Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study

Ebina, Kosuke; Etani, Yuki; Maeda, Yuichi; Okita, Yasutaka; Hirao, Makoto; Yamamoto, Wataru; Hashimoto, Motomu; Murata, Koichi; Hara, Ryota; Nagai, Koji; Hiramatsu, Yuri; Son, Yonsu; Amuro, Hideki; Fujii, Takayuki; Okano, Takaichi; Ueda, Yo; Katayama, Masaki; Okano, Tadashi; Tachibana, Shotaro; Hayashi, Shinya; Kumanogoh, Atsushi; Okada, Seiji; Nakata, Ken

doi:https://doi.org/10.1136/rmdopen-2023-003160

アクセス数:102件（2024-05-26 23:58 集計）

固定URL: https://hdl.handle.net/11094/93204

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
RMDOpen_9_3	pdf	なし	1.43 MB	13	2023.11.28

Creative Commons : 表示 - 非営利

論文情報

ファイル出力

タイトル	Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study
著者	NRID 1000070612076 1000070612076 researchmap permalink k-ebina k-ebina Scopus Author ID 8415453300 8415453300 著者名 Ebina, Kosuke
	NRID 1000060898930 1000060898930 ORCID 0000-0001-5741-5969 0000-0001-5741-5969 researchmap permalink Yetani0302 Yetani0302 著者名 Etani, Yuki
	NRID 1000010815658 1000010815658 Scopus Author ID 56655338200 56655338200 著者名 Maeda, Yuichi
	著者名 Okita, Yasutaka
	NRID 1000010527708 1000010527708 Scopus Author ID 8883255100 8883255100 著者名 Hirao, Makoto
	著者名 Yamamoto, Wataru
	NRID 1000060512845 1000060512845 著者名 Hashimoto, Motomu
	NRID 1000060806793 1000060806793 著者名 Murata, Koichi
	NRID 1000010597107 1000010597107 著者名 Hara, Ryota
	NRID 1000030572458 1000030572458 著者名 Nagai, Koji
	NRID 1000070850072 1000070850072 著者名 Hiramatsu, Yuri
	著者名 Son, Yonsu
	著者名 Amuro, Hideki
	NRID 1000030911557 1000030911557 著者名 Fujii, Takayuki
	著者名 Okano, Takaichi
	著者名 Ueda, Yo
	著者名 Katayama, Masaki
	NRID 1000050754826 1000050754826 著者名 Okano, Tadashi
	著者名 Tachibana, Shotaro
	NRID 1000020437487 1000020437487 著者名 Hayashi, Shinya
	NRID 1000010294125 1000010294125 researchmap permalink read0051725 read0051725 Scopus Author ID 6602726311 6602726311 著者名 Kumanogoh, Atsushi
	NRID 1000030448435 1000030448435 ORCID 0000-0002-5107-8209 0000-0002-5107-8209 researchmap permalink okadaseiji okadaseiji Scopus Author ID 35079139100 35079139100 著者名 Okada, Seiji
	NRID 1000000283747 1000000283747 researchmap permalink ken-nakata ken-nakata Scopus Author ID 7402151308 7402151308 著者名 Nakata, Ken
キーワード等	antirheumatic agents
	glucocorticoids
	rheumatoid arthritis
	tumor necrosis factor inhibitors
内容	Ebina K., Etani Y., Maeda Y., et al. Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. RMD open 9, (2023); https://doi.org/10.1136/rmdopen-2023-003160.
抄録	OBJECTIVES: This multicentre retrospective study in Japan aimed to assess the retention of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors (JAKi), and to clarify the factors affecting their retention in a real-world cohort of patients with rheumatoid arthritis. METHODS: The study included 6666 treatment courses (bDMARD-naïve or JAKi-naïve cases, 55.4%; tumour necrosis factor inhibitors (TNFi) = 3577; anti-interleukin-6 receptor antibodies (aIL-6R) = 1497; cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA4-Ig) = 1139; JAKi=453 cases). The reasons for discontinuation were divided into four categories (ineffectiveness, toxic adverse events, non-toxic reasons and remission); multivariate Cox proportional hazards modelling by potential confounders was used to analyse the HRs of treatment discontinuation. RESULTS: TNFi (HR=1.93, 95% CI: 1.69 to 2.19), CTLA4-Ig (HR=1.42, 95% CI: 1.20 to 1.67) and JAKi (HR=1.29, 95% CI: 1.03 to 1.63) showed a higher discontinuation rate due to ineffectiveness than aIL-6R. TNFi (HR=1.28, 95% CI: 1.05 to 1.56) and aIL-6R (HR=1.27, 95% CI: 1.03 to 1.57) showed a higher discontinuation rate due to toxic adverse events than CTLA4-Ig. Concomitant use of oral glucocorticoids (GCs) at baseline was associated with higher discontinuation rate due to ineffectiveness in TNFi (HR=1.24, 95% CI: 1.09 to 1.41), as well as toxic adverse events in JAKi (HR=2.30, 95% CI: 1.23 to 4.28) and TNFi (HR=1.29, 95%CI: 1.07 to 1.55). CONCLUSIONS: TNFi (HR=1.52, 95% CI: 1.37 to 1.68) and CTLA4-Ig (HR=1.14, 95% CI: 1.00 to 1.30) showed a higher overall drug discontinuation rate, excluding non-toxicity and remission, than aIL-6R.
出版者	NLM (Medline)
収録物名	RMD open
巻(号)	9(3)
刊行年月	2023-08-18
言語	英語
ハンドルURL	https://hdl.handle.net/11094/93204
eISSN	20565933
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1136/rmdopen-2023-003160
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	RMD open. 2023, 9(3)
DC.title	Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study
DC.creator	Ebina, Kosuke
	Etani, Yuki
	Maeda, Yuichi
	Okita, Yasutaka
	Hirao, Makoto
	Yamamoto, Wataru
	Hashimoto, Motomu
	Murata, Koichi
	Hara, Ryota
	Nagai, Koji
	Hiramatsu, Yuri
	Son, Yonsu
	Amuro, Hideki
	Fujii, Takayuki
	Okano, Takaichi
	Ueda, Yo
	Katayama, Masaki
	Okano, Tadashi
	Tachibana, Shotaro
	Hayashi, Shinya
	Kumanogoh, Atsushi
	Okada, Seiji
	Nakata, Ken
DC.publisher	NLM (Medline)
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2023-08-18
DC.identifier	https://doi.org/10.1136/rmdopen-2023-003160
DC.subject	antirheumatic agents
	glucocorticoids
	rheumatoid arthritis
	tumor necrosis factor inhibitors
DC.description	Ebina K., Etani Y., Maeda Y., et al. Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. RMD open 9, (2023); https://doi.org/10.1136/rmdopen-2023-003160.
DCTERMS.abstract	OBJECTIVES: This multicentre retrospective study in Japan aimed to assess the retention of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors (JAKi), and to clarify the factors affecting their retention in a real-world cohort of patients with rheumatoid arthritis. METHODS: The study included 6666 treatment courses (bDMARD-naïve or JAKi-naïve cases, 55.4%; tumour necrosis factor inhibitors (TNFi) = 3577; anti-interleukin-6 receptor antibodies (aIL-6R) = 1497; cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA4-Ig) = 1139; JAKi=453 cases). The reasons for discontinuation were divided into four categories (ineffectiveness, toxic adverse events, non-toxic reasons and remission); multivariate Cox proportional hazards modelling by potential confounders was used to analyse the HRs of treatment discontinuation. RESULTS: TNFi (HR=1.93, 95% CI: 1.69 to 2.19), CTLA4-Ig (HR=1.42, 95% CI: 1.20 to 1.67) and JAKi (HR=1.29, 95% CI: 1.03 to 1.63) showed a higher discontinuation rate due to ineffectiveness than aIL-6R. TNFi (HR=1.28, 95% CI: 1.05 to 1.56) and aIL-6R (HR=1.27, 95% CI: 1.03 to 1.57) showed a higher discontinuation rate due to toxic adverse events than CTLA4-Ig. Concomitant use of oral glucocorticoids (GCs) at baseline was associated with higher discontinuation rate due to ineffectiveness in TNFi (HR=1.24, 95% CI: 1.09 to 1.41), as well as toxic adverse events in JAKi (HR=2.30, 95% CI: 1.23 to 4.28) and TNFi (HR=1.29, 95%CI: 1.07 to 1.55). CONCLUSIONS: TNFi (HR=1.52, 95% CI: 1.37 to 1.68) and CTLA4-Ig (HR=1.14, 95% CI: 1.00 to 1.30) showed a higher overall drug discontinuation rate, excluding non-toxicity and remission, than aIL-6R.
DC.rights	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
DC.format	93204
citation_title	Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study
citation_author	Ebina, Kosuke
	Etani, Yuki
	Maeda, Yuichi
	Okita, Yasutaka
	Hirao, Makoto
	Yamamoto, Wataru
	Hashimoto, Motomu
	Murata, Koichi
	Hara, Ryota
	Nagai, Koji
	Hiramatsu, Yuri
	Son, Yonsu
	Amuro, Hideki
	Fujii, Takayuki
	Okano, Takaichi
	Ueda, Yo
	Katayama, Masaki
	Okano, Tadashi
	Tachibana, Shotaro
	Hayashi, Shinya
	Kumanogoh, Atsushi
	Okada, Seiji
	Nakata, Ken
citation_publisher	NLM (Medline)
citation_language	英語
citation_date	2023-08-18
citation_journal_title	RMD open
citation_volume	9
citation_issue	3
citation_doi	https://doi.org/10.1136/rmdopen-2023-003160
citation_public_url	https://hdl.handle.net/11094/93204

閲覧可能ファイル

論文情報

論文詳細を表示